ISSN: 0975-3583,0976-2833

VOL13, ISSUE 08, 2022

# **ORIGINAL RESEARCH**

## Histopathological Study of Tumour and Tumour Like Lesions of Bone

<sup>1</sup>Dr. Anvita Nilekani, <sup>2</sup>Dr. Thippeswamy M.T.R., <sup>3</sup>Dr. Indumathi S.

 <sup>1</sup>Assistant Professor, Department of Pathology, ESI Medical College and Postgraduate Institute of Medical Science & Research (PGIMSR), Bengaluru, Karnataka, India
 <sup>2</sup>Professor, Department of Pathology, JJM Medical College, Davangere, Karnataka, India
 <sup>3</sup>Associate Professor, Department of Pathology, Sambhram Institute of Medical Sciences and Research, Kolar, Karnataka, India

## **Correspondence:**

Dr. Anvita Nilekani Assistant Professor, Department of Pathology, ESI Medical College and Postgraduate Institute of Medical Science & Research (PGIMSR), Bengaluru, Karnataka, India

## Abstract

**Background:** In this study, we wanted to evaluate the bone tumours and tumour-like lesions as they have a very diverse morphology and overlapping patterns. Also, bone microenvironment is an ideal site for metastasis.

**Materials and methods:** This was a hospital based retrospective and prospective study, conducted among 65 patients who presented with bone tumour and tumour-like lesions to the Department of Pathology, JJM Medical College, Davangere, over a period of 5 years with 3 years of retrospective from June 2014 to May 2017 and 2 years of prospective from June 2017 to May 2019 after obtaining clearance from Institutional Ethics Committee and written informed consent from the study participants.

**Results:** Bone tumours and tumour-like lesions comprised of 0.7% of all the neoplasms diagnosed during the study period. Of which, benign bone tumours formed the majority (70.8%).Most of the cases were seen in  $2^{nd}$  decade, femur (43.1%) being the most common site. Osteochondroma was the most common tumour overall with 25 cases (38.6%) followed by giant cell tumour with 10 cases (15.4%). Osteosarcoma was the most common malignant tumour (6.2%). The histopathological and clinic-radiological correlation showed perfect agreement.

**Conclusion:** Bone tumours and tumour-like lesions are mostly diagnosed on histopathology. Correlating with clinical and radiological data is of utmost importance. Benign bone tumours are most commonly encountered with propensity for long bones, especially femur. Immunohistochemistry is of limited value and no set makers are easily available for diagnosing and differentiating bone tumours.

Keywords: Bone Tumours, Benign, Malignant, Osteochondroma, Osteosarcoma

## Introduction

The skeletal system of the body provides mechanical and structural support. The bone is a connective tissue which is composite in nature due to presence of various components such as minerals, water, collagen, non-collagenous proteins, lipids etc., which helps in its continuous process of growth and remodelling; thus providing the tensile strength to the body.<sup>[1]</sup> The complex pathology of the skeletal system leads to broad spectrum of diseases, including those caused by genetic (sporadic and inherited), malformative, inflammatory, metabolic, circulatory, traumatic, iatrogenic, and neoplastic disorders; and thereon having various morphological expression. Bone tumours, including both neoplasms and various conditions

ISSN: 0975-3583,0976-2833 VOL13, ISSUE 08, 2022

that may simulate them, is one of the most challenging areas in surgical pathology for several reasons. First and the foremost being that bone tumours are uncommon, making it difficult to acquire the necessary skill to diagnose their histological variants and mimics. The pathology training programs have unsatisfactory expertise to provide medical students and young pathologists with the knowledge needed to diagnose these lesions accurately and precisely.<sup>[2]</sup> The correct diagnosis requires careful incorporation of radiological imaging studies and clinical findings. Bearing in mind that the implications of a single diagnosis on a patient can be profound, the study of these lesions becomes of paramount importance. Skeletal cancers may arise in a bone as primary tumours, or as a consequence of the metastatic dissemination of tumour cells from distant sites and thereby giving rise to secondary or tertiary tumours. Progression of malignant tumour in bone is nurtured by the multipotent bone marrow stromal cells and the complex cellular environment that they give rise to, including hematopoietic stem cells, bone marrow endothelial cells, osteoblasts, osteoclasts and their precursors. They adapt and remodel the bone marrow microenvironment. This leads to enhancement of tumorigenicity by changing the genotype and phenotype of cancer cells in bone. This is demonstrated by the cultured bone cells that have been in contact with cancer cells for extended time periods which have the ability to transform non-tumorigenic cells to tumorigenic cells, thus making it apparent that bone cells undergo phenotypic and genotypic modifications during skeletal cancer progression.<sup>[2]</sup> Constituents of the complex bone milieu contribute significantly to the growth and proliferation of primary cancers, such as osteosarcoma or myeloma and also aid in the process of metastasis of epithelial-derived cancers such as prostate or breast cancer.<sup>[2]</sup>Bone tumours and tumour-like lesions are rare among all the tumours of human body. Bone tumours are known for their diversities. And this diverse nature of it makes it crucial to diagnose them correctly and treat them adequately. [3]

### Aims and Objectives

- 1. To study the distribution of bone tumours and tumour-like lesions.
- 2. To elaborate the spectrum of bone tumour and tumour-like lesions by histopathological examination and to correlate with the clinico-radiological data.
- 3. To classify these lesions by WHO classification 2013.

#### Materials and methods

This was a hospital-based retrospective and a prospective study, conducted among 65 patients who presented with bone tumour and tumour-like lesions to the Department of Pathology, JJM Medical College, Davangere, over a period of 5 years with 3 years of retrospective from June 2014 to May 2017 and 2 years of prospective from June 2017 to May 2019 after obtaining clearance from Institutional Ethics Committee and written informed consent from the study participants.

#### **Inclusion Criteria**

All the histologically diagnosed tumours and tumour-like lesions of bone in patients irrespective of their age and sex.

#### **Exclusion Criteria**

- 1. Infectious and inflammatory lesions of bone
- 2. Metabolic lesions of bone
- 3. Haematological malignancies with bone marrow involvement

ISSN: 0975-3583,0976-2833 VOL13, ISSUE 08, 2022

### **Study Procedure**

The excision biopsy samples were collected and fixed in 10% formalin and were grossly examined. The bony bits and soft tissue were segregated. The soft tissue was sent for processing. The hard bony bits were subjected to decalcification with formic acid and concentrated formalin in 3:1 ratio. The large bone specimens were sawed into smaller bits and then subjected for decalcification. After adequate decalcification, the tissue was processed under Leica tissue processor and embedded in paraffin blocks. Sections of  $3\mu$  to  $5\mu$  thick were cut using Leica rotator microtome, and haematoxylin and eosin stained slides were obtained. Immunohistochemistry was done as and when required. The slides were observed under light microscope; histopathological diagnosis was made and classified accordingly. The radiological and clinical details given were analysed and correlated with that of histopathological diagnosis.

## **Statistical Methods**

Statistical analysis was done in the form of frequency tables, ratios and percentages. Cohen's kappa value was derived to know the clinic-radiological and histopathological correlation. The formula and the criteria used were:

$$\kappa=\frac{p_o-p_e}{1-p_e}=1-\frac{1-p_o}{1-p_e},$$

 $p_o$  = the relative observed agreement  $p_e$  = the hypothetical probability of chance agreement

- 0 =agreement equivalent to chance.
- 0.1-0.20 =slight agreement.
- 0.21 0.40 =fair agreement.
- 0.41 0.60 =moderate agreement.
- 0.61 0.80 = substantial agreement.
- 0.81 0.99 = near perfect agreement
- 1 = perfect agreement

### Sample Size Estimation

Prior to beginning of the study, according to the pilot study done for two years (2015 and 2016), a total of 20 cases of bone tumours and tumour-like lesions were reported in our institution, with an average of 10 cases per year.

For the study to be statistically significant, according to the previous studies; a minimum of 50 cases should be included. Hence, the duration of the present study was taken as four years (including three years retrospective and two years prospective) Sample size estimation formula:

 $n = Z^2 P Q / e^2$ 

n: sample size

Z: z score for 95% confidence interval= 1.96

P: Estimated proportion of bone tumour and tumour like lesions in population = 0.007 Q: 1-P= 0.994 e: margin of error= 5% = 0.05 After calculation n= 10

For five-year study: 10x5=50

Estimated sample size- 50 cases (minimum)

ISSN: 0975-3583,0976-2833

VOL13, ISSUE 08, 2022

Total histopathology	63597		100%					
Bone biopsies	300		0.5%					
Bone tumours	65		0.1%					
Ir	ncidence	of bone tumours						
Category		Frequency Percentage (%				<b>%</b> )		
Benign		46			7	0.8		
Malignant		07			1	0.7		
Tumour-like lesi	ons	12			1	8.5		
Total		65			1	100		
Dis	tributior	n of bone t	um	ou	irs			
A 70		Gender				Total		
Age		Male		Female			Total	
≤10	03	08.8%	00	)	00%	03	04.7	
11-20	12	35.3%	10	5	51.6%	28	43.0	
21-30	12	35.3%	08	8	25.8%	20	30.8	
31-40	04	11.8%	03	3	09.7%	07	10.8	
41-50	02	05.8%	03	3 09.7%		05	07.7	
51-60	00	00%	0	1 03.2%		01	01.5	
≥60	01	03.0%	00	0 00%		01	01.5	
Total	100%	3	1	100%	65	100%		
Combined Age and Gender Distribution of Cases								
Table 1								

#### Results

Bone biopsies were 300 in number (0.5%). Of which, 65 cases of bone tumours were seen. Thus, bone tumours made up to 0.1% of the total biopsies, 0.7% of all the tumours and 21.7% of the total bone biopsies.

The benign tumours were in predominance with 46 cases out of the total 65 cases (70.8%). Followed by tumour-like lesions with 12 cases (18.5%) and 07 cases of malignant tumours (10.7%).

Among the males, the cases ranged from 7 to 62 years of age; majority were in second and third decade (35.3%) with the mean age of 23 years. In female, the cases ranged from 11-45 vears: the majority being in 2<sup>nd</sup> decade of life (51.6%) with the mean age of 24.4 years. Among the 46 benign tumours, the age group ranged from 07 to 62 years, mean age being 23.5 years. The benign cases showed male sex preponderance with 27 cases and 19 cases were seen in females. The male to female ratio in benign lesions were 1.4: 1. The age group of males with benign lesions ranged from 07 to 62 cases, mean being 24.4 years. The age group of females with benign lesions ranged from 11 to 45 years, mean being 22.4 years.In the twelve tumour-like lesions, the age ranged from 8 to 40 years, mean age being 20.8 years. There was seen female majority with seven cases, ratio of male to female being 1: 1.4. The age group of females ranged from 15 to 40, mean age being 22.4 years. Five male cases ranged from 8 to 36 years of age with mean being 18.6 years. Of the seven malignant tumours, the age ranged from 12 to 52 years; mean age being 30.1 years. There was female sex predilection among the malignant tumours. Male to female ratio was 1:2.5 The two cases of male, ages were 22 and 33 years; mean age being 27.5 years. The five female malignant cases, age ranged from 12 to 52 years; mean age being 30.4 years. Most of the paediatric tumours (0-16 years) were benign. Tumour-like lesions peaked in second decade. Malignant lesions showed equal predominance in second to third decade.

ISSN: 0975-3583,0976-2833 VOL13, ISSUE 08, 2022

Age		Т	umour Behaviour	
(Years)	Benign	Malignant	Tumour-Like Lesions	Total
<10	02	00	01	03
≤10	04.3%	00.0%	08.3%	
11-20	19	02	07	28
11-20	41.4%	28.7%	58.3%	
21-30	16	02	02	20
21-30	34.8%	28.7%	16.7%	
31-40	05	01	02	08
51-40	10.8%	14.2%	16.7%	
41-50	03	01	00	04
41-30	06.5%	14.2%	00.0%	
51 (0	00	01	00	01
51-60	00.0%	14.2%	00.0%	
>60	01	00	00	01
≥60	02.2%	00.0%	00.0%	
Total	46	07	12	65
Total	tal $100\%$ $100\%$ $100\%$		100%	100%
Ag	e Distribu	tion of Cases	s Based on Tumour Beha	viour
Caralan		Т	umour Behaviour	
Gender	Benign	Malignant	Tumour-like Lesions	Total
Male	27	02	05	34
Male	58.7%	28.6%	41.7%	34
Female	19	05	07	31
remaie	41.3%	71.7%	58.3%	51
Total	46	07	12	65
Total	100%	100%	100%	05
Gender D	istributio	n of Cases Ba	ased on the Behaviour of	the Tumour
		Ī	Table 2	

Most of the tumours in both males and female were benign, with male sex preponderance (58.7%). Malignant lesions showed and tumour-like lesions were seen in majority in females with 71.7% and 58.3% respectively.

<b>Bone Involved</b>	Site Frequency		Total	Percentage(%)	
	Proximal	07			
Femur	Shaft	01	28	43.1	
	Distal	20			
Tibia	Proximal	04	08	12.3	
Tibla	Distal	04	08		
Fibula	Proximal	01	01	01.5	
Humerus	Proximal	05	08	12.3	
numerus	Distal	03	08	12.5	
Radius	Proximal	01	03	04.6	
Kaulus	Distal	02	05	04.6	
Vertebra	Sacrum	02	02	03.1	
Craniofacial	Maxilla	04	12	10.5	
	Mandible	04	12	18.5	

ISSN: 0975-3583,0976-2833

VOL13, ISSUE 08, 2022

Site Proximal Distal Proximal Distribution Site Proximal Distal Proximal Proximal Proximal Proximal Maxilla Mandible - Se Distributio	n of Benign Bo Frequency 03 03 01 07 of Malignant I Frequency 01 01 01 01 02 01 02 03 01 12 on of Tumour- <i>Table 3</i>	<b>Total</b> 06 01 07 <b>Bone Tu</b> <b>Total</b> 02 01 02 01 02 01 05 01 12	Percentage (%) 85.7 14.3 100 mours Percentage (%) 42.3 13.3 13.3 04.4 15.6 04.4 100					
Site Proximal Distal Proximal Distribution Site Proximal Distal Proximal Proximal Proximal Proximal Maxilla Mandible -	Frequency         03           03         03           01         07           of Malignant I            Frequency         01           01         01           01         01           01         01           01         01           01         01           01         01           02         01           03         01           12         12	<b>Total</b> 06 01 07 <b>Bone Tu</b> <b>Total</b> 02 01 02 01 02 01 05 01 12	Percentage (%) 85.7 14.3 100 mours Percentage (%) 42.3 13.3 13.3 04.4 15.6 04.4 100					
Site Proximal Distal Proximal Distribution Site Proximal Distal Proximal Proximal Proximal Proximal Proximal Proximal Maxilla	Frequency         03           03         03           01         07           of Malignant I         01           of Malignant I         01           of 01         01           01         01           01         01           01         01           01         01           01         02           01         02           03         01	<b>Total</b> 06 01 <b>07</b> <b>Bone Tu</b> <b>Total</b> 02 01 02 01 05 01	Percentage (%) 85.7 14.3 100 mours Percentage (%) 42.3 13.3 13.3 04.4 15.6 04.4					
Site Proximal Distal Proximal Distribution Site Proximal Distal Proximal Proximal Proximal Proximal Proximal Proximal Maxilla	Frequency         03           03         03           01         07           of Malignant I         01           of Malignant I         01           of 01         01           01         01           01         01           01         01           01         01           02         01           02         03	<b>Total</b> 06 01 07 <b>Bone Tu</b> <b>Total</b> 02 01 02 01 02 01 05	Percentage (%) 85.7 14.3 100 mours Percentage (%) 42.3 13.3 13.3 04.4 15.6					
Site Proximal Distal Proximal Distribution Site Proximal Distal Proximal Proximal Proximal Proximal Proximal Proximal Maxilla	Frequency         03           03         03           01         07           of Malignant I         Frequency           01         01           01         01           01         01           01         01           01         01           01         01           02         01           02         01	<b>Total</b> 06 01 07 <b>Bone Tu</b> <b>Total</b> 02 01 02 01	Percentage (%) 85.7 14.3 100 mours Percentage (%) 42.3 13.3 13.3 04.4					
Site Proximal Distal Proximal Distribution Site Proximal Distal Proximal Proximal Proximal Proximal Proximal Proximal Proximal Proximal	Frequency         03           03         03           01         07           of Malignant I         07           of Malignant I         01           01         01           01         01           01         01           01         01           01         01           01         01           01         01           01         01           01         01           01         01           01         01           01         01           01         01           01         01	<b>Total</b> 06 01 07 <b>Bone Tu</b> <b>Total</b> 02 01 02	Percentage (%) 85.7 14.3 100 mours Percentage (%) 42.3 13.3 13.3					
Site Proximal Distal Proximal Distribution Site Proximal Distal Proximal Proximal Proximal Proximal Proximal	Frequency         03           03         03           01         07           of Malignant I	<b>Total</b> 06 01 07 <b>Bone Tu</b> <b>Total</b> 02 01 02	Percentage (%) 85.7 14.3 100 mours Percentage (%) 42.3 13.3 13.3					
Site Proximal Distal Proximal Distribution Site Proximal Distal Proximal Proximal Proximal Proximal	Frequency         03           03         03           01         07           of Malignant I	<b>Total</b> 06 01 <b>07</b> <b>Bone Tu</b> <b>Total</b> 02 01	Percentage (%)         85.7         14.3         100         mours         Percentage (%)         42.3         13.3					
Site Proximal Distal Proximal Distribution of Site Proximal	Frequency         03           03         03           01         07           of Malignant I         Frequency           01         01	<b>Total</b> 06 01 <b>07</b> <b>Bone Tu</b> <b>Total</b>	Percentage (%) 85.7 14.3 100 mours Percentage (%) 42.3					
Site Proximal Distal Proximal Distribution of Site	Frequency 03 03 01 07 07 0f Malignant I Frequency	<b>Total</b> 06 01 <b>07</b> <b>Bone Tu</b> <b>Total</b>	Percentage (%) 85.7 14.3 100 mours Percentage (%)					
Site Proximal Distal Proximal Distribution o	Frequency 03 03 01 07 07 07 06 Malignant 1	<b>Total</b> 06 01 <b>07</b> Bone Tu	Percentage (%) 85.7 14.3 100 mours					
Site Proximal Distal Proximal	Frequency           03           03           01           07	<b>Total</b> 06 01 <b>07</b>	Percentage (%)           85.7           14.3           100					
Site Proximal Distal Proximal	Frequency           03           03           01           07	<b>Total</b> 06 01 <b>07</b>	Percentage (%)           85.7           14.3           100					
<b>Site</b> Proximal Distal	Frequency           03           03           01	<b>Total</b> 06 01	Percentage (%)           85.7           14.3					
<b>Site</b> Proximal Distal	<b>Frequency</b> 03 03	<b>Total</b> 06	<b>Percentage (%)</b> 85.7					
<b>Site</b> Proximal	<b>Frequency</b> 03	Total	Percentage (%)					
Site	Frequency	Total	Percentage (%)					
	Ū							
e Distribution	ı of Benign Bo	Site-wise Distribution of Benign Bone TumoursBone InvolvedSiteFrequencyTotalPercentage						
	-	-						
	46	46	100					
-	02	02	04.4					
canal	01							
rnal auditory								
asal bone	01							
Femporal	02	07	15.2					
Mandible	01							
Maxilla	02							
Sacrum	02	02	04.4					
Distal	02	02	04.4					
Proximal	00		04.4					
Distal	03	06	13.0					
Proximal	03	0.6	12.0					
Proximal	01	01	02.2					
	04	07	15.2					
		17	71.2					
		10	41.2					
	· · ·	Total	Percentage (%)					
<b>C:</b> 4a	Ene en en en	Tatal	$\mathbf{D}_{\mathbf{a}} = \mathbf{D}_{\mathbf{a}} = $					
tion of Cases	Based on the	Site of L	esion					
			100					
-			04.6					
canal		02	04.6					
-	01							
	01							
-								
	Site Proximal Shaft Distal Proximal Distal Proximal Distal Proximal Distal Proximal Distal Proximal Distal Sacrum Maxilla Mandible Femporal Sasal bone	asal bone01rnal auditorycanal01-0365tion of CasesBased on the SSiteFrequencyProximal02Shaft01Distal16Proximal03Distal04Proximal03Distal04Proximal03Distal04Proximal03Distal04Proximal01Proximal02Maxilla02Maxilla02Maxilla02Vandible01Cemporal02Vasal bone01	Image of the second systemImage of the second systemraal auditory01raal auditory01canal01-0303656565tion of Cases Based on the Site of LSiteFrequencyProximal02Shaft011919Distal16Proximal030307Distal04Proximal030101Proximal030306Proximal000202Sacrum020202Maxilla020101Femporal020202					

ISSN: 0975-3583,0976-2833 VOL13, ISSUE 08, 2022

Femur was the most common site involved with 43.1%; The majority was localised to distal femur (30.7%) and among these, the knee joint per se (distal femur and proximal tibia), were involved in 15 cases. Craniofacial bones comprised of 18.5% cases, followed by tibia (12.3%) and humerus (12.3%). Radius and fibula comprised of 4.6% and 1.5% cases respectively. Among the smaller bones, only metatarsals were involved in three cases (4.6%). Vertebra was involved in two cases (3.1%) both involving the sacral part of the vertebra.

Most of the benign bone tumours were located in femur (41.2%) followed by craniofacial region (15.2%). Within the femur, the distal part of the femur was most commonly involved. Within the craniofacial bones, maxilla and temporal bone were involved in two cases each. Rest of the bones, including mandibles, nasal bones and bone of the external auditory canal were involved in single cases each. Tibia and humerus were involved in seven and six cases respectively. Within the tibia, the distal portion was mostly involved, whereas the humerus showed equal proportion of proximal and distal involvement. Two cases involved the distal radius, sacral region of vertebra and metatarsals each.

The malignant cases were localised predominantly in femur (85.7%) followed tibia (14.3%). The tumour-like lesions are mostly located in craniofacial region predominantly, especially the mandible was involved in three case.

Location	Frequency	Percentage					
Epiphysis	20	30.8%					
Epi-metaphysis	08	12.3%					
Metaphysis	28	43.1%					
Meta-diaphysis	04	06.2%					
Diaphysis	02	03.1%					
Joint space	03	04.5%					
Total	65	100%					
<b>Distribution of Cases Base</b>	ed on the Locatio	n within the Bone					
Diagnosis	Frequency	Percentage (%)					
Osteochondroma	25	38.6					
Synovial chondromatosis	03	04.6					
Chondroblastoma	01	01.5					
Chondrosarcoma	01	01.5					
Osteoid osteoma	02	03.1					
Osteoma	05	07.7					
Osteosarcoma	04	06.2					
Ewing's sarcoma	01	01.5					
Giant cell tumour	10	15.4					
Aneurysmal bone cyst	02	03.1					
Simple bone cyst	01	01.5					
Fibrous dysplasia	09	13.8					
Metastasis	01	01.5					
Total	65	100					
<b>Distribution of Cases Based on Histopathological Diagnosis</b>							
Table 4							

Within the bone, the metaphysis was majorly involved with 28 cases (43.1%) followed by epiphysis (30.8%). The epiphyseal-metaphyseal and the metaphyseal-diaphyseal junction were involved in 12.3% and 6.2% cases respectively. Two cases (3.1%) were located in the diaphyseal region of the bone. The joint space of the knee was involved in three cases (4.5%). Based on histopathological diagnosis, majority of the cases were benign followed by tumour-like lesions and least were malignant cases. The benign cases were osteochondroma majorly,

ISSN: 0975-3583,0976-2833 VOL13, ISSUE 08, 2022

synovial chondromatosis, giant cell tumour, osteoma and osteoid osteoma. The tumour-like lesions comprised of cystic lesions of bone like two cases of aneurysmal bone cysts and a case of simple bone cyst. Nine cases of fibrous dysplasia of bone were also seen. The malignant cases were mostly primary malignant lesions of bone, osteosarcoma being predominant followed by chondroblastoma and chondrosarcoma. There was a single case of metastatic bone deposits.

Osteochondroma was diagnosed in 25 cases (38.6%). Mostly they were solitary lesions. Two of the 25 cases showed multiple lesions, suggesting osteochondromatosis. This was followed by 10 cases of giant cell tumour (15.4%) all of which were benign in nature with no features of anaplasia. There were three cases (4.6%) of synovial chondromatosis, all of them presented in the knee joint. The osteoma (7.7%) and osteoid osteoma (3.1%) were seen in five and two cases respectively. All the osteomas were located in craniofacial region.

Among the tumour-like lesions, fibrous dysplasia (13.8 %) was seen in majority with nine cases. A single case of simple bone cyst (1.5%) and two cases (3.1%) of aneurysmal bone cysts were seen.

There were four cases (6.2%) of osteosarcoma among the malignant lesions. One case each of chondroblastoma and chondrosarcoma (1.5%).Chondrosarcoma was of lower grade. One case of Ewing's sarcoma was seen for which CD99 marker showed diffuse membranous positivity. One single case of metastasis to bone was seen.

Diagnosia			nder			a <b>4</b> :a	Frequency		Demonstrage	
Diagnosis	Μ	ale	Fe	emale	K	atio	Fre	quency	Percentage	
Osteochondroma	17	50.0%	08	25.8%	5 2	.1:1		25	38.6	
Synovial										
chondromatosis	02	05.8%	01	03.2%	ó ź	2:1		03	04.6	
Chondroblastoma	01	02.9%	00	00.0%	ó	1:0		01	01.5	
Chondrosarcoma	00	00.0%	01	03.2%	ó (	0:1		01	01.5	
Osteoid osteoma	01	02.9%	01	03.2%	ó	1:1	02		03.1	
Osteoma	00	00.0%	05	16.1%	ó (	0:5		05	07.7	
Osteosarcoma	01	02.9%	03	09.7%	, D	1:1		04	06.2	
Ewing's sarcoma	01	02.9%	0	00.0%	б (	0:1		01	01.5	
Giant cell tumour	06	17.6%	04	13.1%	5 1	.5:1		10	15.4	
Aneurysmal bone										
cyst	01	02.9%	01	03.2%	ó	1:1		02	03.1	
Simple bone cyst	00	00.0%	01	03.2%	ó (	0:1		01	01.5	
Fibrous dysplasia	04	12.1%	05	16.1%	6 0	0.8:1		09	13.8	
Metastasis	00	00.0%	01	03.2%	ó (	0:1		01	01.5	
Total	34	100	31	100	1	.1:1			100	
Gender	Distrib	ition of	Bone ť	Tumour	and T	<u>'umour</u>	·-like	Lesions		
Diagnosis				ge(in yea				Mean	Total	
Diagnosis	<10	10-20	20-30	30-40	40-50	50-60	>60	Age	I Utal	
Osteochondroma	02	13	07	01	01		01	20.9	25	
Synovial										
chondromatosis				03				33.0	03	
Chondroblastoma		01						42.0	01	
Chondrosarcoma					01			45.0	01	
Osteoid osteoma		02						13.0	02	
Osteoma		02	02		01			27.4	05	
Osteosarcoma		02	02					19.3	04	
Ewing's sarcoma				01				37.0	01	

ISSN: 0975-3583,0976-2833

VOL13, ISSUE 08, 2022

Giant cell tumor		01	07	01	01			28.1	10
ABC				02				38.0	02
SBC		01						15.0	01
Fibrous dysplasia	01	06	02					17.0	09
Metastasis						01		52.0	01
Total	03	28	20	08	04	01	01	23.8	65
Age Distribution of Bone Tumour and Tumour-like Lesions									
			T	able 5					

Among the benign tumours, osteochondroma, synovial chondromatosis and giant cell tumours showed male preponderances with male to female ratio of 2:1 to 1.5:1. All the cases of osteoma were seen in females, whereas osteoid osteoma showed no sex predilection.

Aneurysmal bone cysts showed equal incidence in males and females whereas as single case of simple bone cyst and cases of fibrous dysplasia showed higher incidence in females.

Among the malignant cases, a single case of chondroblastoma and chondrosarcoma was seen in a male and a female respectively. Four cases of osteosarcoma were seen in which three were in females and one in male. Ewing's sarcoma was seen in a male and metastasis to bone was seen in female. The majority of osteochondroma cases were seen in second and third decade of life with 13 and seven cases respectively. Two were seen in below ten years and one in above 60 years of age. All the three cases of synovial chondromatosis were seen in fourth decade. One case each of chondroblastoma and chondrosarcoma were seen in second and fifth decade.

Two cases of osteoid osteoma were seen in second decade as well as osteomas were seen in second and third decade. Osteosarcoma cases were seen in 1227 years of age. Mean age was 19.3 years.

The giant cell tumours were seen predominantly in  $3^{rd}$  decade of life with mean age being 28.1 years.Both the cases of aneurysmal bone cyst were seen in  $4^{th}$  decade and a single case of simple bone cyst was seen in  $2^{nd}$  decade. The fibrous dysplasia cases presented mostly in  $2^{nd}$  decade, the mean age was 17 years. Ewing's sarcoma and metastatic bone tumour presented in  $4^{th}$  and  $6^{th}$  decade respectively.

Based on the World health organisation classification of bone tumours, majority of cases were chondrogenic tumours (46.1%), benign comprising the larger portion of these with 28 cases, one case of intermediate but rarely metastasizing type and one case of malignant bone tumour. Among the eleven osteogenic tumours, seven cases were benign (10.8%) and four cases (6.1%) of malignant.


The ten giant cell tumour cases (15.4%) were categorised under osteoclastic giant cell rich tumours of intermediate nature (locally aggressive, rarely metastasizing).

Tumour-like lesions were categorised under tumour of unknown neoplastic nature. Of which, ten cases (15.4%) were benign and two (3.1%) were of categorised under intermediate, locally aggressive type.

The Ewing's sarcoma and metastatic tumour (3.1%) were under miscellaneous category of WHO bone tumours.


ISSN: 0975-3583,0976-2833

VOL13, ISSUE 08, 2022



ISSN: 0975-3583,0976-2833

VOL13, ISSUE 08, 2022



#### Discussion

In a study done by Mohammed et.al, in West India, incidence of bone tumours was 1.9% over the period of nine years.<sup>[3]</sup> In our study, we encountered 65 cases of bone tumours and tumour-like lesions which comprised of 0.7% of all the tumours which is marginally higher than the SEER statistics.

In our study, we encountered one case of pathological fracture. Katchy et al. reported 35% cases with pathological fracture.<sup>[4]</sup> 11 of our cases were associated with limited range of motion, seven of them had visible deformity.

The benign tumours were in predominance in most of the studies. Among the benign bone tumours, osteochondroma was the most common lesion in various studies, like that of Baena-Ocampo et al., Rhusto et al., and Kumavat et al.,<sup>[5,6,7]</sup> which corresponded with that of our study with 54.3% cases. Giant cell tumour of bone is found to have higher incidence (20% of all primary bone tumours) in south Indian population.<sup>[8]</sup>

Excluding all the hematopoietic neoplasms involving the bone marrow, osteosarcoma (57.1%) was the most common malignant bone tumour in our study,

Among the tumour-like lesions, fibrous dysplasia (66.7%) was the most common lesion which correlated with all that of Settakorn et. al, Baena- Ocampo et. al., Rhusto et al and Kumavat et al.<sup>[9]</sup>

The Cohen's kappa value for the given study was 0.82 which showed excellent agreement between histopathological and clinico-radiological diagnosis. Similar results were seen in a study done Negash et al. with a kappa value of 0.84.<sup>[10]</sup>

In our study, we encountered chondrogenic tumours in majority, out of which, osteochondromawas seen in highest numbers (38.6%). Various other studies have had a similar result.

Five cases of osteoma were seen in our study, all of them were located in craniofacial region. All five were seen in females with a mean age of 27 years. Histologically, all of them had compact lamellated bone with scant intervening fibro vascular stroma, suggesting a compact type of osteoma. Boffano et al., also reported female predilection and majority of them had similar histopathological findings as our study.

### Conclusion

A thorough clinico-radiological examination is must before histopathological evaluation. An excellent correlation between clinico-radiological and histopathological diagnosis is usually

ISSN: 0975-3583,0976-2833 VOL13, ISSUE 08, 2022

seen. Therefore, histopathological diagnosis should follow after careful evaluation of clinical data and radiological findings. For this, a close coordination between the operating orthopaedician, radiologists and the pathologists is suggested. Also, it is imperative for a histopathologist to have reasonable knowledge of radiological interpretation in cases where a formal report is unavailable. Morphology of the lesions along with clinico-radiological correlation is of utmost importance for diagnosing a bone tumour. Immunohistochemistry is of limited value and is of varied help in diagnosing these lesions. However, it helps in diagnosing the small round blue cell tumours of the bone as well as an occult primary in case of metastasis to bone. In the era of chemotherapy, a cytogenetic studies and flow cytometric studies are being increasingly used in bone tumours so as to target a specific gene or molecule and thus predict response to treatment. These techniques might be useful in future for patient-centric, tailor-made targeted drug therapies.

### References

- 1. Bullough P. Orthopedic pathology. 5<sup>th</sup> edn. Maryland Heights, Mo.: Mosby/Elsevier 2010.
- 2. Bronner F, Farach-Carson M. Bone and Cancer. 1<sup>st</sup> edn. Dordrecht: Springer 2009.
- 3. Mohammed A, Isa HA. Patterns of primary tumours and tumour like lesions of bone in Zaria. Northern Nigeria: a review of 127 cases. West Afr J Med 2007;26(1):37-41.
- 4. Katchy KC, Ziad F, Alexander S, Gad H, Motaal MA. Malignant bone tumours in Kuwait: a 10 year clinicopathological study. IntOrthop2005;29(6):406-11.
- 5. Baeno-Ocampo LC, Ramirez-Perez E, Linares-Gonzalez LM, Delgado-Chavez R. Epidemiology of bone tumours in Mexico City: retrospective: clinicopathological study of 566 patients at a referral institution. Ann DiagnPathol 2009;13(1):16-21.
- 6. Rhutso Y, Laishram RS, Sharma LD, Debnath K. Histopathological evaluation of bone tumors in a tertiary care hospital in Manipur, India. J Med Soc 2013;27(2):135-9.
- 7. Kumavat P, Gadgil N, Chaudhari C, Rathod U, Kshirsagar G, Margam S. Bone tumors and tumor-like lesions: A study in a tertiary care hospital, Mumbai. Ann Pathol Lab Med 2017;4(1):10-18.
- 8. Chakarun CJ, Forrester DM, Gottsegen CJ, Patel DB, White EA, Matcuk GR. Giant cell tumor of bone: review, mimics and new developments in treatment. Radiographics 2013;33(1):197-211.
- 9. Settakorn J, Lekawanvijit S, Arpornchayanon O, Rangdaeng S, Vanitanakom P, Kongkarnka S, et al: Spectrum of bone tumours in Chiang Mai University Hospital, Thailand, according to WHO classification 2002: study of 1,001 cases. J Med Assoc Thai 2006;89(6):780-7.
- 10. Negash BE, Adamasie D, Wamisho BL, Tinsay MW. Bone tumours at Addis Ababa University, Ethiopia: agreement between radiological and histopathologicaldiagnosis, a 5 year analysis at Black-Lion Teaching Hospital. Int J MedMedSci2009;1(4):119-25.